Company intelligence / Profile preview
Coagulant Therapeutics
Berkeley, CA, United Statescoagulanttherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CT-001, their lead product, has demonstrated superior potency and safety compared to recombinant Factor VIIa (rFVIIa) in multiple murine acute bleeding models. It shows faster clearance, decreased systemic exposure risk, and efficacy under coagulopathic conditions[2].
- Therapeutic areas
- OtherWomen's HealthHematologyNeurology
- Modalities
- Biologicsrecombinant proteinsantibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Coagulant Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coagulant Therapeutics.